⏱ 18 min read
Hospital 366 Days · Case No. 13
The hospital’s year does not end at 365. It runs to 366, and keeps going.
Call her Jean. Age, occupation, location, and any potentially identifying details have been changed. The clinical pattern is a composite reconstructed from cases that American emergency rooms see repeatedly over a year, and it does not represent any specific patient.
People tend to assume lung cancer begins with a lung symptom: a cough, phlegm, breathlessness. But in a fair number of cases the first sign comes from somewhere other than the chest. Here, a month of lung cancer abdominal pain was the starting point of a stage 4 diagnosis. Every test ordered at the beginning was aimed at the belly.
A current smoker is about 15 times more likely to die of lung cancer than someone who never smoked. (PLOS Medicine 2008) In an Australian population cohort, people who smoked more than 35 cigarettes a day reached a lung cancer hazard ratio of about 39 compared with never-smokers. (TID 2022) Someone with 50 pack-years who still smokes a pack a day sits at the high end of the commonly cited 15-to-30-times range.
In the United States, an annual low dose CT scan, or LDCT, is recommended for lung cancer screening in people aged 50 to 80 who have a 20 pack-year smoking history and either still smoke or quit within the past 15 years. (USPSTF 2021) Jean met every part of that definition. But she had no regular primary care physician, and she had never had an LDCT.
Stage 4 non-small cell lung cancer, or NSCLC, with metastasis has historically carried a five-year net survival of about 4%. (JCO 2019) Since the mid-2010s, though, immune checkpoint inhibitors and targeted therapy have raised that survival meaningfully. In U.S. SEER real-world data, the one-year survival for stage 4 NSCLC improved by about 2.09 percentage points each year after 2014. (Wei 2024) The same diagnosis followed a different path ten years ago than it does now.
This is not the story of every 64-year-old American woman. It is a look, in numbers, at how lung cancer in a long-term heavy smoker can show itself first through abdominal symptoms rather than the chest, and at where a single LDCT could have fit in the years before. Below are the days that brought her in.
The Scan That Was Looking at Her Stomach
Jean was 64 and retired. She lived alone, with two grown children in other states. She had no regular primary care physician. When she caught a cold she went to a local urgent care, and she renewed her own coverage each year on the Medicare site. The last physical exam she could remember was the pre-operative workup before a hysterectomy, more than a decade earlier.
About a month before, her whole abdomen had begun to ache in a vague way. It was not a pain she could put a finger on, and it moved among the upper belly, the flanks, and the lower abdomen. Nausea, vomiting, and diarrhea came and went over a span of days. There was a burning feeling when she urinated. She had not cut back on food, yet she had lost about 6 pounds over the past ten days.
Because the belly was the suspect, the tests went to the belly. A colonoscopy the previous fall had found a few sigmoid polyps and internal hemorrhoids. Neither explained the current pain. An abdominal ultrasound a few weeks earlier was unremarkable. When the abdominal pain did not let up, her outpatient physician decided to order a CT of the abdomen and pelvis without contrast.
Her smoking history was long. She had started in her late teens, reached about 50 pack-years, and still smoked a pack a day. She denied alcohol and illicit drugs. Her surgical history was two items: a gallbladder removal and a hysterectomy. The morning cough and phlegm she had carried for years were, to her, just part of being a smoker. There was a little breathlessness climbing two flights of stairs, but no night sweats, and until a few weeks earlier she had no idea there was anything in her lungs at all.
The CT images of the abdomen and pelvis went to the reading room. Reviewing the abdominal images, the radiologist found something at the bottom of the scan, in the bases of both lungs. The outpatient physician got a phone call. What the CT had shown was not the source of the abdominal pain it had been ordered to investigate. It was a small finding low in the image, in the left lower lobe.
From Belly Pain to a Lung Mass
Last fall. Colonoscopy: sigmoid polyps and internal hemorrhoids. Neither was the cause of the current pain.
A few weeks ago. Abdominal ultrasound: unremarkable. The pain did not ease.
Early last week. With nearly a month of abdominal pain, nausea, vomiting, diarrhea, painful urination, and about 6 pounds of weight loss, the outpatient physician ordered a non-contrast CT of the abdomen and pelvis.
Midweek. The CT read came back. Several small low-density nodules in the liver, new compared with the prior year’s images. A moderate pericardial effusion around the heart. A 1.6 cm cyst on the right ovary. And low in the scan, a spiculated mass in the left lower lobe.
Later that week. A chest CT was added. A roughly 3.4 cm spiculated mass in the left lower lobe, with necrotic enlargement of mediastinal and supraclavicular lymph nodes. Malignancy with metastasis was strongly suspected. Scattered sclerotic lesions in the thoracic spine and sternum could not rule out metastasis.
End of the week. The moderate pericardial effusion and the mildly elevated troponin and NT-proBNP prompted a cardiology referral, but an outpatient slot was hard to get. The outpatient physician arranged a direct transfer to a higher-level facility with an emergency department that could provide oncology consultation and admission.
Day of transfer. Jean was transferred from an outside emergency department to the higher-level facility. She still did not know exactly what was causing her abdominal pain.
Lung Cancer Abdominal Pain: What the ED Workup Found
Triage vitals: blood pressure 138/82, heart rate 96, respiratory rate 18, oxygen saturation 94% on room air, temperature 36.7°C, no fever. She had mild breathlessness but denied night sweats and any new chest pain.
The results from the outside facility were as follows. Troponin 44 ng/L, repeated at three hours at 42 (just above the upper reference limit, with no real trend). NT-proBNP 812 pg/mL. BUN and creatinine 22 and 1.3 (mildly reduced kidney function). Alkaline phosphatase (ALP) 149 U/L (elevated). Sodium 132 mEq/L (mild hyponatremia). CBC normal. Urinalysis showed bilirubin 2+, ketones 3+, and protein 2+. No single value was decisive on its own. The pattern they formed was.
The combined imaging picture was a 3.4 cm spiculated mass in the left lower lobe together with necrotic mediastinal and supraclavicular lymphadenopathy. That pattern fits malignancy with metastasis most closely. The multiple new low-density nodules in the liver, absent on the earlier images, made metastasis strongly suspected. The sclerotic lesions in the thoracic spine and sternum were hard to separate from bone metastasis. The moderate pericardial effusion read as imaging evidence of tumor reaching the chest cavity and the pericardium. The 1.6 cm right ovarian cyst was an incidental finding.
The Admitting team entered the following orders. Schedule an image-guided biopsy for tissue diagnosis. Oncology consultation. A transthoracic echocardiogram to assess the pericardial effusion. Cardiology consultation. Additional staging imaging, with the choice between brain MRI and a bone scan or PET-CT left to oncology. Supportive care with oxygen, fluids, analgesia, and anti-nausea medication. Admission to the oncology floor.
Plain-Language Reference
| Term | What It Means in Plain Language |
|---|---|
| Spiculated lung mass | A mass in the lung with spiky, radiating edges. On imaging, this is the shape that most strongly suggests cancer. |
| Mediastinal and supraclavicular nodes | Lymph nodes in the center of the chest and just above the collarbone. They are among the first routes by which lung cancer spreads. |
| Necrotic lymphadenopathy | Lymph nodes that are swollen and have dead tissue at their center. It is one appearance of spread. |
| Pericardial effusion | Fluid collecting inside the sac around the heart. In larger amounts it can press on the heart and limit its beating. |
| Stage 4 (metastatic) disease | Cancer that has spread to organs far from where it began. In lung cancer, the liver, bones, brain, adrenal glands, and the other lung are common sites. |
| Pack-year | A unit of cumulative smoking. One pack a day for one year equals one pack-year. Fifty pack-years describes a lifetime total. |
| LDCT (low dose CT) | A lung-screening CT with far less radiation than a standard CT. In the U.S. it is recommended annually for eligible smokers. |
| Troponin | A protein that leaks into the blood when heart muscle is injured or strained. The trend often matters more than a single value. |
| NT-proBNP | A marker that rises when the heart is under pressure or volume strain. It goes up in heart failure, pericardial effusion, and similar states. |
| Hyponatremia | A blood sodium level below the normal range. It can accompany advanced cancer. |
| ALP (alkaline phosphatase) | An enzyme made mainly in the liver and bone. It can rise when there is liver or bone metastasis. |
| Sclerotic bone lesion | A patch of bone that looks denser and whiter than usual. It has several causes, metastasis among them. |
| Clinical Marker | Patient’s Presentation | Significance & Reference Literature |
|---|---|---|
| 50 Pack-Years, Current Smoker | Screening-eligible, never screened | A current smoker’s lung cancer death risk is about 15 times that of a never-smoker (PLOS Medicine 2008). In heavy smokers the hazard ratio has been reported as high as 39 (TID 2022). |
| Spiculated LLL Mass + Necrotic Nodes | About 3.4 cm | Spiky margins together with necrotic nodal enlargement form the imaging pattern that fits malignancy with metastasis most closely. |
| New Liver Nodules + Sclerotic Bone Lesions | New since last year | A multi-organ pattern of spread. It points toward stage 4 (metastatic) disease. |
| Moderate Pericardial Effusion | With elevated troponin and NT-proBNP | A malignant pericardial effusion marks advanced disease and poor prognosis. One-year survival with lung cancer is about 16% (JCO 2015), and about 22.7% in a SEER NSCLC cohort (PLOS One 2019). |
| Mild Hyponatremia | Na 132 | It can accompany advanced malignancy. In some cases the mechanism is SIADH, the inappropriate release of antidiuretic hormone. |
| Stage 4 NSCLC Prognosis | Metastatic | Historical five-year net survival about 4% (JCO 2019). After the immunotherapy era began, stage 4 NSCLC one-year survival rose by about 2.09 points each year after 2014 (Wei 2024). |
A month of belly pain, tests aimed only at the abdomen, and the answer low in the image, in the base of a lung.
From the Reviewer · Eleanor Hayes, M.D.
(A) When the first sign of lung cancer is not in the lung
In cases like this, the idea that the first symptom may not be in the chest is nothing new clinically. Lung cancer is more likely than most common cancers to already carry distant metastasis at the time of diagnosis, and the first symptom not uncommonly starts at a site of spread, such as the liver, bone, brain, or adrenal gland. What the patient brings in is often a nonspecific complaint: vague abdominal discomfort, loss of appetite, weight loss, bone pain, headache, a change in vision. For a 64-year-old smoker with abdominal pain, the first differential a clinician reaches for in the office is the familiar list: gallstones, gastritis, diverticulitis, constipation, a urinary tract infection. Chest imaging is not on that list.
(B) How much smoking raises the risk
That smoking is the single largest risk factor for lung cancer has been settled for a long time. The most frequently cited figure is that a current smoker is about 15 times more likely to die of lung cancer than a never-smoker. (PLOS Medicine 2008) But that number splits widely by intensity and duration. In a large Australian cohort, the hazard ratio for people smoking more than 35 cigarettes a day reached about 39 times that of never-smokers. (TID 2022) A pattern of 50-plus pack-years with a current pack-a-day habit sits at the high end of the commonly cited 15-to-30-times range.
(C) How lung cancer can present first through the abdomen
There are three main routes by which lung cancer shows up first as an abdominal symptom. First, liver metastasis. Lung cancer commonly involves the liver, and stretching of the liver capsule or involvement of nodes near the portal vein can cause vague right upper quadrant or epigastric pain. Second, adrenal metastasis. Lung cancer frequently involves the adrenal glands, which can present first as flank or back pain. Third, nonspecific systemic symptoms. In advanced lung cancer, loss of appetite, weight loss, nausea, and fatigue can dominate, and both patient and clinician often think of the digestive tract first. This is the route by which lung cancer abdominal pain most often reaches the office before any chest symptom does. This patient’s new liver nodules were the imaging finding that best matched the first route.
(D) LDCT screening: who it is for, and what it catches
When the USPSTF updated its lung cancer screening recommendation in 2021, it advised an annual low dose CT for adults aged 50 to 80 with a 20 pack-year history who currently smoke or quit within the past 15 years. (USPSTF 2021) That lowered the age floor by five years and the pack-year threshold by 10 from the earlier 2013 recommendation of 55 to 80 and 30 pack-years. The basis was the NLST trial, in which lung cancer mortality in the LDCT arm fell by about 20% compared with chest X-ray. (NLST analysis) At 64, 50 pack-years, and still smoking, she met every part of the recommendation. Had she had a regular primary care physician, she was a patient for whom one LDCT a year would have been advised.
(E) The weight of an everyday symptom called “smoker’s cough”
For a long-term smoker, a morning cough, phlegm, and mild breathlessness settle into daily life over time. The patient does not register them as a new change and does not report them to a clinician. As a result of this pattern, a few of the most common early signals the lung could send go unrecorded in the chart. The line “the old cough was always there” first appears when the patient reaches the emergency room, and by then the mass is often already visible on imaging. In clinical terms, this everyday symptom is not a synonym for being asymptomatic. It is better classified as an unreported symptom.
(F) Pericardial effusion as imaging evidence of chest involvement
When a pericardial effusion accompanies lung cancer, it suggests the tumor has reached the neighboring structures of the chest. Fluid fills the pericardial space through direct invasion, through spread along the mediastinal lymphatics, or through hematogenous metastasis. (Sadiq 2021) A malignant pericardial effusion is itself a marker that affects both stage and prognosis. One-year survival in malignant pericardial effusion with lung cancer was about 16% in one study (JCO 2015) and about 22.7% in a SEER-based NSCLC study. (PLOS One 2019) In the latter, median survival was 10.5 months in the group that received chemotherapy, against 4.3 months in the group that did not. Treatment itself moved the prognosis.
(G) The context of mildly elevated troponin and NT-proBNP
This patient’s troponin of 44 then 42 ng/L and NT-proBNP of 812 are not decisive numbers on their own. But in a 64-year-old with a clinically meaningful pericardial effusion, a left lower lobe mass, and mediastinal nodal enlargement, the two values rising together read as a marker of the strain placed on the pericardium and myocardium. The context, not the absolute value, sets the meaning. Immediate pericardiocentesis was not called for at the ED stage, but using an echocardiogram to assess the volume of the effusion and its effect on the heart’s beating, particularly the ventricular filling pattern, is standard.
(H) Mild hyponatremia and SIADH
A sodium of 132 is a common mild hyponatremia on its own. But advanced lung cancer, small cell lung cancer in particular, is known to be accompanied by the inappropriate release of antidiuretic hormone, or SIADH. It is reported in non-small cell lung cancer too, though less often. In a patient whose diagnostic picture is moving toward stage 4 lung cancer, a sodium of 132 is better weighed against a tumor-related cause than explained by dehydration alone. This patient also had ketonuria, bilirubinuria, and proteinuria, leaving open the chance that a short stretch of reduced food and fluid intake and a tumor effect were acting at the same time.
(I) What the liver and bone findings mean for staging
The multiple low-density liver nodules absent on last year’s images read differently from a simple benign cyst, because they are new. The scattered sclerotic lesions in the thoracic spine and sternum, set next to the elevated ALP, are also hard to separate from bone metastasis. A tumor at one site, plus nodal enlargement, plus new liver nodules, plus sclerotic bone lesions, is the combination that fits stage 4 (metastatic) disease on imaging. Final staging is settled after tissue type is confirmed and after molecular testing and additional imaging, such as brain MRI and PET-CT.
(J) What the published trajectories show
It is hard to generalize a path before the tissue type is confirmed. But within the broad category of stage 4 NSCLC, the published figures run as follows.
- The historical five-year net survival for stage 4 NSCLC has been reported at about 4%. (JCO 2019)
- In U.S. SEER data, one-year survival for stage 4 NSCLC rose by about 2.09 percentage points each year after 2014, and the timing of that shift lines up with the arrival of immune checkpoint inhibitors. (Wei 2024)
- In the five-year analysis of KEYNOTE-189, five-year OS in the pembrolizumab-plus-chemotherapy group was 19.4%, against 11.3% for chemotherapy alone. (Merck 2022)
- In a SEER-based stage 4 NSCLC cohort, one-, two-, and three-year OS in the immunotherapy group was 37.8%, 23.5%, and 16.7%, against 29.0%, 14.2%, and 8.5% in the non-immunotherapy group. (Ni 2024)
That a malignant pericardial effusion is present is a variable that pushes the prognosis somewhat to one side, but the PLOS One data showing longer median survival in the chemotherapy group suggests the treatment decision itself can move the outcome. Where this patient lands is set by tissue type, molecular profile, and the decisions made by the patient and the team.
(K) What Bends the Curve
About five decisions open up for this patient over a short span of time. None of them is the kind that can be answered in the emergency room.
- Tissue type confirmed by image-guided biopsy. Non-small cell versus small cell, and if non-small cell, the subtype such as adenocarcinoma versus squamous cell carcinoma. The whole set of treatment options turns on this.
- Molecular testing and PD-L1 expression. Testing for driver mutations including EGFR, ALK, ROS1, BRAF, KRAS G12C, MET, RET, and NTRK. PD-L1 TPS changes eligibility for immunotherapy and the combination used.
- Management of the pericardial effusion. An asymptomatic moderate effusion may be observed or followed at set intervals. If pressure symptoms or reduced output appear, pericardiocentesis is considered, and a pericardial window if it recurs.
- The decision on quitting smoking and supportive care. It affects treatment tolerance, complication risk, and the breadth of options at the next step.
- Concurrent palliative care referral. In advanced lung cancer, patients referred to palliative care early and concurrently have been reported to live longer than those who were not. (Temel 2010, NEJM)
The answers to these five belong to the patient and the oncology and palliative care teams. The figures laid out above are only the distribution before those decisions are made.
Two Costs, One Decision Window
| Clinical & Behavioral Scenarios | Estimated Facility Billing | Patient Out-of-Pocket (PPO) |
|---|---|---|
| (1) Stage 4 lung cancer diagnostic workup plus initial admission (5 to 7 days) | $40,000 to $80,000 | ~$8,500 (annual OOP max hit) |
| (2) Hypothetical: one LDCT screening a year while eligible | $100 to $400 (per scan) |
Often $0 (covered as prevention) |
| (3) Add: pericardial drainage plus first-line systemic therapy for 12 months | +$120,000 to $300,000 | Annual OOP max re-hit |
| (4) Five-year course: repeated admissions, treatment, imaging, and palliative care | +$300,000 to $700,000 | Annual OOP max + income-loss risk |
Sources: USPSTF 2021 (LDCT recommendation); JCO 2019 (stage 4 NSCLC survival); PLOS One 2019 (malignant pericardial effusion survival). Facility and out-of-pocket figures are scenario estimates for a typical PPO and vary by plan and region.
For a PPO member who hits the annual out-of-pocket maximum each year either way, the dollar gap between the scenarios narrows quickly. The difference that does not narrow is timing. The variable that decided where a single LDCT could have fit was not the price of the scan. It was whether there was a primary care physician to recommend that scan each year. This admission finished the work of identifying the cause of the lung cancer abdominal pain. The next decision, confirming the tissue type and treatment eligibility, begins on the oncology team’s outpatient calendar.
The same pattern of a serious finding discovered while looking for something else runs through the case of a month of back pain that turned out to be multiple myeloma. The same smoking-related route to a head and neck cancer appears in the oropharyngeal cancer case where alcohol and smoking overlapped. How a patient with no regular primary care physician is affected at a decisive moment is laid out in the case of older men living alone who arrive in the emergency room.
Tools for Reading Longevity and Health Numbers
A single result rarely tells the whole story. Three calculators that help frame longevity, blood-panel, and fitness numbers against age-matched references.
· Life Calculator (Longevity Estimate)
· Blood Work Decoder (Cardiac & Metabolic Panel Reader)
· Fitness Age Calculator (Cardiopulmonary Fitness Estimate)
Jean was admitted to the oncology floor for tissue diagnosis and staging. The emergency room finished one thing. It accounted for why a month of tests aimed at the belly had not found the cause of her lung cancer abdominal pain. The cause was the mass low in the image, in the left lower lobe.
An image-guided biopsy was scheduled within the next few days, with molecular testing to follow depending on the result. PD-L1 expression, the presence or absence of a driver mutation, and the timing of any pericardial intervention are the agenda for the next outpatient visit. Which first-line treatment fits this patient is decided after those results, among the oncology and palliative care teams and the patient herself.
This article is for general information and does not provide medical advice. The case described is a composite reconstructed from publicly reported clinical patterns and does not represent any specific patient. New or persistent abdominal pain, unexplained weight loss, and questions about lung cancer screening for anyone who meets the smoking-related criteria can be raised with a primary care physician or through an emergency room visit. Prescribed medications should never be stopped or adjusted on your own.
Take care of yourself. Nobody else will do it for you.
Wilbur P is the editor of Manclub, leading coverage across health and life. His work is research-driven and built on primary sources a reader can verify – written for men in the second half of life who would rather know than believe. Based in Florida, still learning and still in the fight. Corrections, questions, story tips: [email protected].